Will the two biosimilars sold by foreign companies be successful in the domestic market?
Lilly and MSD are expected to introduce biosimilars in the domestic market.
According to the industry concerned on the 18th, Lilly and MSD have turned in approval applications for biosimilars of ‘Lantus(insulin glargine),’ a Sanofi’s basal insulin, and ‘Enbrel(etanercept),’ a Pfizer’s TNF-Alpha ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
